TY - JOUR T1 - Evaluating the neutralizing ability of a CpG-adjuvanted S-2P subunit vaccine against SARS-CoV-2 Variants of Concern JF - medRxiv DO - 10.1101/2021.03.19.21254000 SP - 2021.03.19.21254000 AU - Chia-En Lien AU - Tsun-Yung Kuo AU - Yi-Jiun Lin AU - Wei-Cheng Lian AU - Meei-Yun Lin AU - Luke Tzu-Chi Liu AU - Yu-Chi Chou AU - Charles Chen Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/03/22/2021.03.19.21254000.abstract N2 - Vaccination is currently the best weapon to control the COVID-19 pandemic. However, an alarming number of novel variants termed Variants of Concern (VoC) were found to harbor mutations that diminished the neutralizing capacity of antibodies elicited by the vaccines. We have investigated the neutralizing titers of antibodies from sera of humans and rats immunized with the MVC-COV1901 vaccine against pseudoviruses coated with the wildtype, D614G, B.1.1.7, or B.1.351 spike proteins. Rats vaccinated with two doses of adjuvanted S-2P retained neutralization activities against the B.1.351 variant, albeit with a slight reduction compared to wildtype. Phase 1 vaccinated subjects showed more reduced neutralization abilities against the B.1.351 variant. The study is among the first, to our knowledge, to demonstrate dose-dependent neutralizing responses against VoCs, particularly against B.1.351, from different doses of antigen in a clinical trial for a subunit protein COVID-19 vaccine. The appearance of vaccine escape variants is a growing concern facing many current COVID-19 vaccines and therapeutics. Strategies should be adopted against the ever-changing nature of these variants. The observations of this study grant us valuable insight into preemptive strikes against current and future variants.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04487210Funding StatementNo external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The protocol has been approved by the 132nd meeting of Research Ethics Committee C of the National Taiwan University Hospital (NTUH) on Aug 3, 2020. The committee is organized under, and operates in accordance with, the Good Clinical Practice guidelines and governmental laws and regulations. Approval by the Ministry of Health and Welfare is mandatory before project implementation. The duration of this approval is six months (Aug 6, 2020 to Feb 5, 2021). The investigator is required to report Serious Adverse Events and Unanticipated Problems in accordance with the governmental laws and regulations and NTUH requirements and apply for a continuing review not less than six weeks prior to the approval expiration date. Chairman of Research Ethics Committee C: Daniel Fu-Chang Tsai, M.D. NTUH-REC No. 202007029MSC Protocol No. CT-COV-11All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated during and analyzed during the current study are available from the corresponding author on reasonable request. ER -